KMT2A and acute lymphoblastic leukemia: High-throughput genomics and profiling studies have significantly contributed to uncovering the unique biology of KMT2A-rearranged infant ALL, defining its distinctive gene expression and DNA methylation profiles [4,5,6,7,8,9] and elucidating its remarkably silent mutational landscape [10,11].